BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 30710686)

  • 1. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation.
    Magenau J; Braun T; Gatza E; Churay T; Mazzoli A; Chappell G; Brisson J; Runaas L; Anand S; Ghosh M; Riwes M; Pawarode A; Yanik G; Reddy P; Choi SW
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1682-1688. PubMed ID: 30710686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.
    Holtan SG; DeFor TE; Lazaryan A; Bejanyan N; Arora M; Brunstein CG; Blazar BR; MacMillan ML; Weisdorf DJ
    Blood; 2015 Feb; 125(8):1333-8. PubMed ID: 25593335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.
    Alousi A; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Pidala J; Anderlini P; Boyiadzis M; Bredeson CN; Cahn JY; Cairo MS; Gadalla SM; Hashmi SK; Gale RP; Kanda J; Kamble RT; Kharfan-Dabaja MA; Litzow MR; Ringden O; Saad AA; Schultz KR; Verdonck LF; Waller EK; Yared JA; Holtan SG; Weisdorf DJ
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):270-278. PubMed ID: 30292009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.
    Zheng CC; Zhu XY; Tang BL; Zhang XH; Zhang L; Geng LQ; Liu HL; Sun ZM
    Bone Marrow Transplant; 2017 Jan; 52(1):88-94. PubMed ID: 27376453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
    Omer AK; Weisdorf DJ; Lazaryan A; Shanley R; Blazar BR; MacMillan ML; Brunstein C; Bejanyan N; Arora M
    Biol Blood Marrow Transplant; 2016 May; 22(5):879-83. PubMed ID: 26743342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
    McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.
    El-Jawahri A; Li S; Antin JH; Spitzer TR; Armand PA; Koreth J; Nikiforow S; Ballen KK; Ho VT; Alyea EP; Dey BR; McAfee SL; Glotzbecker BE; Soiffer RJ; Cutler CS; Chen YB
    Biol Blood Marrow Transplant; 2016 May; 22(5):910-8. PubMed ID: 26748160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
    Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.
    Solh M; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1403-1409. PubMed ID: 27095692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation.
    Holtan SG; Zhang L; DeFor TE; Bejanyan N; Arora M; Rashidi A; Lazaryan A; Kotiso F; Blazar BR; Wagner JE; Brunstein CG; MacMillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1884-1889. PubMed ID: 31128328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.
    Konuma T; Kato S; Oiwa-Monna M; Ishii H; Tojo A; Takahashi S
    Leuk Lymphoma; 2016 Sep; 57(9):2126-32. PubMed ID: 26769297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.
    Rangarajan HG; Pereira MSF; Brazauskas R; St Martin A; Kussman A; Elmas E; Verneris MR; Gadalla SM; Marsh SGE; Paczesny S; Spellman SR; Lee SJ; Lee DA
    Transplant Cell Ther; 2021 Nov; 27(11):926.e1-926.e10. PubMed ID: 34407489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.
    Mehta RS; Holtan SG; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Alousi AM; Pidala J; Abdel-Azim H; Ahmed I; Aljurf M; Askar M; Auletta JJ; Bhatt V; Bredeson C; Chhabra S; Gadalla S; Gajewski J; Gale RP; Gergis U; Hematti P; Hildebrandt GC; Inamoto Y; Kitko C; Khandelwal P; MacMillan ML; Majhail N; Marks DI; Mehta P; Nishihori T; Olsson RF; Pawarode A; Diaz MA; Prestidge T; Qayed M; Rangarajan H; Ringden O; Saad A; Savani BN; Seo S; Shah A; Shah N; Schultz KR; Solh M; Spitzer T; Szer J; Teshima T; Verdonck LF; Williams KM; Wirk B; Wagner J; Yared JA; Weisdorf DJ
    Blood Adv; 2019 May; 3(9):1441-1449. PubMed ID: 31053571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.
    Mehta RS; Holtan SG; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Alousi AM; Pidala J; Abdel-Azim H; Agrawal V; Ahmed I; Al-Homsi AS; Aljurf M; Antin JH; Askar M; Auletta JJ; Bhatt VR; Chee L; Chhabra S; Daly A; DeFilipp Z; Gajewski J; Gale RP; Gergis U; Hematti P; Hildebrandt GC; Hogan WJ; Inamoto Y; Martino R; Majhail NS; Marks DI; Nishihori T; Olsson RF; Pawarode A; Diaz MA; Prestidge T; Rangarajan HG; Ringden O; Saad A; Savani BN; Schoemans H; Seo S; Schultz KR; Solh M; Spitzer T; Storek J; Teshima T; Verdonck LF; Wirk B; Yared JA; Cahn JY; Weisdorf DJ
    J Clin Oncol; 2020 Jun; 38(18):2062-2076. PubMed ID: 32364845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts.
    Arcuri LJ; Hamerschlak N; Rocha V; Bonfim C; Kerbauy MN
    Transplant Cell Ther; 2021 Sep; 27(9):782.e1-782.e7. PubMed ID: 34146733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.
    Qayed M; Wang T; Hemmer MT; Spellman S; Arora M; Couriel D; Alousi A; Pidala J; Abdel-Azim H; Aljurf M; Ayas M; Bitan M; Cairo M; Choi SW; Dandoy C; Delgado D; Gale RP; Hale G; Frangoul H; Kamble RT; Kharfan-Dabaja M; Lehman L; Levine J; MacMillan M; Marks DI; Nishihori T; Olsson RF; Hematti P; Ringden O; Saad A; Satwani P; Savani BN; Schultz KR; Seo S; Shenoy S; Waller EK; Yu L; Horowitz MM; Horan J
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):521-528. PubMed ID: 29155316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies.
    Inagaki J; Fukano R; Noguchi M; Okamura J
    Int J Hematol; 2017 May; 105(5):676-685. PubMed ID: 28205066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.
    Vrooman LM; Millard HR; Brazauskas R; Majhail NS; Battiwalla M; Flowers ME; Savani BN; Akpek G; Aljurf M; Bajwa R; Baker KS; Beitinjaneh A; Bitan M; Buchbinder D; Chow E; Dandoy C; Dietz AC; Diller L; Gale RP; Hashmi SK; Hayashi RJ; Hematti P; Kamble RT; Kasow KA; Kletzel M; Lazarus HM; Malone AK; Marks DI; O'Brien TA; Olsson RF; Ringden O; Seo S; Steinberg A; Yu LC; Warwick A; Shaw B; Duncan C
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1327-1334. PubMed ID: 28461213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.